New Clinical Trial Tests Immune-Protected Insulin-Producing Cell Implant for Type 1 Diabetes

Encellin, a biotech company, is testing a new approach to Type 1 diabetes that goes beyond daily insulin management. The therapy uses Encapsulated Cell Replacement Therapy (ENCRT)—an implant containing insulin-producing cells taken from donors. The implant is designed with a special membrane meant to shield these cells from the immune system, which in Type 1 diabetes mistakenly attacks and destroys them.

The new clinical trial, called NCT07680673, will test whether this next-generation implant configuration, called ENCRT-103-hPI, can safely work in people with Type 1 diabetes. The study is being conducted in Canada with support from Breakthrough T1D through its Industry Discovery and Development Partnership program.

This new trial builds on findings from Encellin's first-in-human Phase 1 study (NCT06408311), which tested the initial implant design. That earlier study showed promising results: when implants were later removed and examined, they contained viable human islet cells. The tissue around the implants also showed healthy integration and new blood vessel formation, without signs of harmful fibrotic scarring.

These results provided enough evidence to move forward with the next generation of the technology in a larger clinical setting.

The upcoming study will focus on three main goals: determining whether the implant is safe and well-tolerated, examining how the body's tissue responds around the implant, and assessing whether the immune-protective membrane actually works.

Specifically, researchers will evaluate vascular integration—whether new blood vessels grow around the implant to supply oxygen and nutrients—and whether the implant's membrane successfully prevents immune cells from reaching and attacking the transplanted islets. They will also measure how long the transplanted insulin-producing cells survive and remain functional.

Current Type 1 diabetes management relies on insulin therapy—either through injections or pumps—which addresses the symptoms but not the underlying loss of insulin-producing cells. If an immune-protected implant could safely replace those cells, it could potentially allow people with Type 1 diabetes to produce insulin naturally in response to blood sugar changes, rather than relying on external insulin dosing.

However, this trial is an early-stage test. Success in this study would represent progress toward a potential new treatment option, not yet a proven cure or standard therapy.

Origin: finance.yahoo.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.